Tg Therapeutics (TGTX) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to -$235.8 million.
- Tg Therapeutics' Enterprise Value rose 3085.85% to -$235.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$235.8 million, marking a year-over-year increase of 3085.85%. This contributed to the annual value of -$311.0 million for FY2024, which is 4298.32% down from last year.
- As of Q3 2025, Tg Therapeutics' Enterprise Value stood at -$235.8 million, which was up 3085.85% from -$401.6 million recorded in Q2 2025.
- Over the past 5 years, Tg Therapeutics' Enterprise Value peaked at -$139.7 million during Q1 2023, and registered a low of -$523.8 million during Q1 2021.
- In the last 5 years, Tg Therapeutics' Enterprise Value had a median value of -$233.2 million in 2022 and averaged -$277.6 million.
- Its Enterprise Value has fluctuated over the past 5 years, first plummeted by 56872.79% in 2021, then skyrocketed by 5586.76% in 2022.
- Quarter analysis of 5 years shows Tg Therapeutics' Enterprise Value stood at -$314.8 million in 2021, then skyrocketed by 48.64% to -$161.7 million in 2022, then plummeted by 34.53% to -$217.5 million in 2023, then plummeted by 42.98% to -$311.0 million in 2024, then grew by 24.18% to -$235.8 million in 2025.
- Its Enterprise Value was -$235.8 million in Q3 2025, compared to -$401.6 million in Q2 2025 and -$420.3 million in Q1 2025.